, Tracking Stock Market Picks
Enter Symbol:
BIODEL INC. (BIOD) [hlAlert]

up 3,041.17 %

BIODEL INC. (BIOD) rated Sell by Argus

Posted on: Friday,  Sep 19, 2008  9:25 AM ET by Argus

Argus rated Sell BIODEL INC. (NASDAQ: BIOD) on 09/19/2008, when the stock price was $21.36. Since
then, BIODEL INC. has lost 96.82% as of 12/18/2015's recent price of $0.68.
If you would have followed this Argus's recommendation on BIOD, you would have gained 3041.17% of your investment in 2646 days.

Biodel Inc. (Biodel) is a development-stage specialty pharmaceutical company located in Danbury, Connecticut. The Company is focused on the development and commercialization of treatments for endocrine disorders, such as diabetes and osteoporosis. The Company develops product candidates by applying its formulation technologies to existing drugs in order to improve their therapeutic results. The Company?s initial development efforts are focused on peptide hormones. The Company?s advanced product candidate, VIAject, has been studied in two pivotal Phase III clinical trials for the treatment of patients with Type 1 and Type 2 diabetes. Earlier stage product candidates include VIAtab, a sublingual tablet formulation of insulin and two preclinical product candidates for the treatment of osteoporosis. The Company has developed all of its product candidates utilizing its VIAdel technology that allows the Company to study the interaction between peptide hormones and small molecules.

Argus Research is an independent research firm, and our business is producing, distributing and marketing high-quality investment and economic research. Our recommendations - BUY, HOLD and SELL - reflect the judgment of an analyst about a company's prospects as an investment in terms of value, expected growth and risks. Argus Research does not bring companies public, advise companies on mergers and acquisitions, broker trades, make markets in stocks or manage money. Our independence allows us to make critical judgments about companies that we might not be so free to make were we competing for a firm's underwriting business. Because we're not a broker/dealer, we don't have "inventory" of a stock that we have to move with a tainted recommendation. We have developed a six-point system for analyzing the stocks in our Universe of Coverage. We believe that this system
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/19/2008 9:25 AM Sell
as of 12/24/2008
1 Week up  10.35 %
1 Month down  -15.13 %
3 Months down  -31.07 %
1 YTD down  -4.14 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy